Name: ScreenQuest™ Beta-Lactamase Inhibitor Screening Kit
Brand: AAT Bioquest
SKU: 11333
Price: 864 USD
Availability: InStock

ScreenQuest™ Beta-Lactamase Inhibitor Screening Kit

ScreenQuest™ Beta-Lactamase Inhibitor Screening Kit enables accurate quantification of β-lactamase activity and high-throughput inhibitor screening.

Quantitative measurement: Detects nitrocefin hydrolysis with colorimetric readout at 490 nm
Applications: Suitable for HTS screening, kinetic studies, and inhibitor characterization
Flexible format: Can be adapted for use in higher-throughput or automated workflows
Comparable alternative: Functionally similar to Sigma-Aldrich’s β-Lactamase Inhibitor Screening Kit

Avibactam dose response was measured with ScreenQuest™ Beta-Lactamase Inhibitor Screening Kit (Cat#11333) on a 96-well clear bottom plate using a SpectraMax reader (Molecular Devices).

Protocol

SDS

COA

Catalog	Size	Price	Quantity
11333	100 Tests	Price

Overview

The ScreenQuest™ Beta-Lactamase Inhibitor Screening Kit is a sensitive and robust assay tailored for high-throughput screening of HTS of β-lactamase inhibitors. The kit measures β-lactamase activity through the hydrolysis of nitrocefin, a chromogenic cephalosporin substrate, producing a colorimetric product with maximum absorbance at 490 nm. The resulting absorbance signal is directly proportional to enzymatic activity, enabling precise quantitative analysis. This assay is optimized for kinetic and inhibitor studies and is fully compatible with automated HTS platforms for reproducible, large-scale workflows. It provides a dependable solution for identifying and characterizing HTS of β-lactamase inhibitors, supporting antimicrobial resistance research and the development of novel therapeutic strategies.

References

View all 50 references: Citation Explorer

Activity of cefepime, carbapenems and new β-lactam/β-lactamase inhibitor combinations on Enterobacter cloacae complex and Klebsiella aerogenes in Spain (SMART 2016-2022).

Authors:

Rodríguez-Villodres, Ángel and Lepe-Balsalobre, Esperanza and Ortiz De La Rosa, José Manuel and Giner Almaraz, Salvador and González De Herrero, Elisa and Cercenado, Emilia and García-Fernández, Sergio and Benito, Rafael and Ponz Mir, Ricardo and Cantón, Rafael and Lepe, José Antonio

Journal:

JAC-antimicrobial resistance (2024): dlae087

Impact of chromosomally encoded resistance mechanisms and transferable β-lactamases on the activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa.

Authors:

González-Pinto, Lucía and Alonso-García, Isaac and Blanco-Martín, Tania and Camacho-Zamora, Pablo and Fraile-Ribot, Pablo Arturo and Outeda-García, Michelle and Lasarte-Monterrubio, Cristina and Guijarro-Sánchez, Paula and Maceiras, Romina and Moya, Bartolome and Juan, Carlos and Vázquez-Ucha, Juan Carlos and Beceiro, Alejandro and Oliver, Antonio and Bou, Germán and Arca-Suárez, Jorge

Journal:

The Journal of antimicrobial chemotherapy (2024): 2591-2597

Corrigendum to "Activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against isogenic strains of Escherichia coli expressing single and double β-lactamases under high and low permeability conditions" [International Journal of

Authors:

Blanco-Martín, Tania and Alonso-García, Isaac and González-Pinto, Lucía and Outeda-García, Michelle and Guijarro-Sánchez, Paula and López-Hernández, Inmaculada and Pérez-Vázquez, María and Aracil, Belén and López-Cerero, Lorena and Fraile-Ribot, Pablo and Oliver, Antonio and Vázquez-Ucha, Juan Carlos and Beceiro, Alejandro and Bou, Germán and Arca-Suárez, Jorge and ,

Journal:

International journal of antimicrobial agents (2024): 107264

Cefepime-Taniborbactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination.

Authors:

Zhanel, George G and Mansour, Celine and Mikolayanko, Stacey and Lawrence, Courtney K and Zelenitsky, Sheryl and Ramirez, Danyel and Schweizer, Frank and Bay, Denice and Adam, Heather and Lagacé-Wiens, Philippe and Walkty, Andrew and Irfan, Neal and Clark, Nina and Nicolau, David and Tascini, Carlo and Karlowsky, James A

Journal:

Drugs (2024): 1219-1250

A Systematic Review of the Pharmacokinetics and Pharmacodynamics of Novel Beta-Lactams and Beta-Lactam with Beta-Lactamase Inhibitor Combinations for the Treatment of Pneumonia Caused by Carbapenem-Resistant Gram-Negative Bacteria.

Authors:

Rando, Emanuele and Novy, Emmanuel and Sangiorgi, Flavio and De Pascale, Gennaro and Fantoni, Massimo and Murri, Rita and Roberts, Jason A and Cotta, Menino Osbert

Journal:

International journal of antimicrobial agents (2024): 107266

Storage, safety and handling

H-phrase	H303, H313, H333
Hazard symbol	XN
Intended use	Research Use Only (RUO)
R-phrase	R20, R21, R22

Instrument settings

Absorbance microplate reader
Absorbance	490/380 nm
Recommended plate	Clear bottom

Documents

Protocol
Safety Data Sheet
Certificate of Analysis

Telephone
Fax
Email	sales@aatbio.com
International	See distributors
Bulk request	Inquire
Custom size	Inquire
Technical Support	Contact us
Request quotation	Request
Purchase order	Send to sales@aatbio.com
Shipping	Standard overnight for United States, inquire for international

Page updated on December 18, 2025

Component A: Nitrocefin	1 Vial (100 uL)
Component B: β-Lactamase Assay buffer	1 Bottle (10 mL)
Component C: β-Lactamase	1 Vial (Lyophilized Powder)
Component D: Inhibitor, Avibactam	1 Vial ( 1 mM, 50 uL/vial)